Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

Gerstein H. C. , Yusuf S., Holman R. R. , Bosch J., Anand S., Avezum A., ...Daha Fazla

LANCET, cilt.368, ss.1096-1105, 2006 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 368 Konu: 9541
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1016/s0140-6736(06)69420-8
  • Dergi Adı: LANCET
  • Sayfa Sayıları: ss.1096-1105


Background Rosiglitazone is a thiazolidinedione that reduces insulin resistance and might preserve insulin secretion. The aim of this study was to assess prospectively the drugs ability to prevent type 2 diabetes in individuals at high risk of developing the condition.